← Leaderboards
Javier Gordon Ogembo
Beckman Research Institute/City Of Hope
$11,510,265
Attributed
$11,510,265
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $2.1M · FY2014–25$2.5M$1.9M$1.3M$625K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,510,265 · 6
By mechanism
R01$9,070,469 · 2
R21$1,045,582 · 2
R56$858,605 · 1
K01$535,609 · 1
Top collaborators
No co-investigators on record.
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Lorraine Zvichapera Mutsvunguma$672,032
Others in their field
Top investigators on “B-Lymphocytes”
- Barton F Haynes · Duke University$400,419,833
- Lawrence Corey · Fred Hutchinson Cancer Center$83,920,398
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$83,920,398
- Dan H. Barouch · Fred Hutchinson Cancer Center$66,039,430
- Dennis R. Burton · Scripps Research Institute$63,566,673
- Rafi Ahmed · Emory University$62,743,001
Research focus
B-LymphocytesIn VitroGlycoproteinsCellsPreventMalignant NeoplasmsIn VivoProphylacticInfectionAntibodiesAnimal ModelVaccine CandidateVaccine DevelopmentViralImmunizeVirus DiseasesSuccessDesignImmunocompromised HostImmunosuppressionPreventive VaccineKaposi SarcomaTransplant RecipientsHuman Herpesvirus 8
Grant awards (30)
KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Reponses against KSHV Infection$848,656
R01 · FY2025 · AI · contact PI
Unmasking the roles of viral glycoproteins in oral transmission of KSHV$840,264
R01 · FY2025 · CA · contact PI
Unmasking the roles of viral glycoproteins in oral transmission of KSHV$75,469
R01 · FY2025 · CA · contact PI
KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Reponses against KSHV Infection$848,928
R01 · FY2024 · AI · contact PI
Unmasking the roles of viral glycoproteins in oral transmission of KSHV$840,321
R01 · FY2024 · CA · contact PI
Unmasking the roles of viral glycoproteins in oral transmission of KSHV$75,469
R01 · FY2024 · CA · contact PI
KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Reponses against KSHV Infection$851,034
R01 · FY2023 · AI · contact PI
Unmasking the roles of viral glycoproteins in oral transmission of KSHV$816,677
R01 · FY2023 · CA · contact PI
Unmasking the roles of viral glycoproteins in oral transmission of KSHV$73,959
R01 · FY2023 · CA · contact PI
KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Reponses against KSHV Infection$858,048
R01 · FY2022 · AI · contact PI
Unmasking the roles of viral glycoproteins in oral transmission of KSHV$809,710
R01 · FY2022 · CA · contact PI
Unmasking the roles of viral glycoproteins in oral transmission of KSHV$199,999
R01 · FY2022 · CA · contact PI
Unmasking the roles of viral glycoproteins in oral transmission of KSHV$125,000
R01 · FY2022 · CA · contact PI
Unmasking the roles of viral glycoproteins in oral transmission of KSHV$75,469
R01 · FY2022 · CA · contact PI
KSHV Subunit Vaccine Candidates to Elicit Potent Humoral Immune Reponses against KSHV Infection$877,449
R01 · FY2021 · AI · contact PI
Unmasking the roles of viral glycoproteins in oral transmission of KSHV$854,017
R01 · FY2021 · CA · contact PI
A multivalent prophylactic and therapeutic vaccine against EBV infection and EBV-associated malignancies$858,605
R56 · FY2020 · AI · contact PI
Precision Antibody-Based Therapy to Neutralize Epstein-Barr Virus-Associated PTLDs$182,493
R21 · FY2019 · CA · contact PI
A novel VLP vaccine to prevent EBV infection and EBV - associated malignancies$73,278
R21 · FY2019 · CA · contact PI
Characterization of Epstein-Barr virus monoclonal antibodies as tools for diagnosing and prevention of EBV infection in transplant settings$66,520
R21 · FY2019 · CA · contact PI
Precision Antibody-Based Therapy to Neutralize Epstein-Barr Virus-Associated PTLDs$8,598
R21 · FY2019 · CA · contact PI
Precision Antibody-Based Therapy to Neutralize Epstein-Barr Virus-Associated PTLDs$225,765
R21 · FY2018 · CA · contact PI
A novel VLP vaccine to prevent EBV infection and EBV - associated malignancies$176,605
R21 · FY2018 · CA · contact PI
Unmasking the roles of KSHV glycoproteins in virus entry and vaccine development$98,360
K01 · FY2018 · CA · contact PI
A novel VLP vaccine to prevent EBV infection and EBV - associated malignancies$77,331
R21 · FY2018 · CA · contact PI
A novel VLP vaccine to prevent EBV infection and EBV - associated malignancies$234,992
R21 · FY2017 · CA · contact PI
Unmasking the roles of KSHV glycoproteins in virus entry and vaccine development$108,798
K01 · FY2017 · CA · contact PI
Unmasking the roles of KSHV glycoproteins in virus entry and vaccine development$108,808
K01 · FY2016 · CA · contact PI
Unmasking the roles of KSHV glycoproteins in virus entry and vaccine development$109,027
K01 · FY2015 · CA · contact PI
Unmasking the roles of KSHV glycoproteins in virus entry and vaccine development$110,616
K01 · FY2014 · CA · contact PI